Move to topTop
March 02, 2022

TOKYO, JAPAN - March 2, 2022 - Terumo Corporation (TSE: 4543) today announced that Terumo has been included as a constituent of the MSCI Japan ESG Select Leaders Index*, a major index of Environmental, Social and Governance (ESG) investment. It is the first time the company has been selected for the index.

The MSCI Japan ESG Select Leaders Index is a selection of Japanese companies from the top 700 listed by market capitalization. As of December 2021, 222 companies with excellent ratings based on the company's resilience to ESG risks are selected from each industry.

The MSCI Japan ESG Select Leaders Index is also one of the indexes adopted by the Government Pension Investment Fund (GPIF), the world's largest public pension for ESG investment. Terumo is also selected as a constituent of the "FTSE Blossom Japan Index" and the "S&P/JPX Carbon Efficient Index" adopted by GPIF. With this selection, Terumo has been selected in a total of three ESG indexes adopted by GPIF.

As a company responsible for human life and health, Terumo will continue to bring value to stakeholders by striving further to solve the numerous social and environmental issues surrounding healthcare. And consequently, contribute to achieving a sustainable and healthy society.

  • 20220302_EN
  •  

About Terumo Group Sustainability Policy

Terumo considers the realization of the Group Mission as the goal of sustainability activities and resolving healthcare challenges as a sustainability priority for the Group. With this in mind, Terumo will strive to realize a sustainable society as well as the company's sustainable growth by creating social values through advancing healthcare and enhancing patients' quality of life in our main business areas. In response to the COVID-19 pandemic, Terumo has been devoted to supplying a steady supply of medical products and services to healthcare providers and contributing to the prevention and treatment of the disease.
Terumo perceives solving social and environmental issues and responding to social demand as a foundation for business activities. The company will continue to create social value through the Group's unique business offerings and activities.



<Reference>

Terumo Group Sustainability

https://www.terumo.com/sustainability/

MSCI Japan ESG Select Leaders Index

https://www.msci.com/our-solutions/japan-esg-select-leaders-index


 

  • * THE INCLUSION OF TERUMO IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF TERUMO BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.

    番号付き注釈

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.